eldavojohn writes: "Patents aren't just a software thing and while Bilski's Dismissal didn't shake the ground for software, it certainly is making waves in the biotech community. You may recall Prometheus v. Mayo in which doctors fought a biotech startup's methodology patents. Well, medical method patents (like Prometheus and another) are now being reconsidered on orders by the Supreme Court of certiorari (judicial review). Stocks of biotech startups jumped as this news broke but the question still remains how the lower Federal Circuit court will rule when it reconsiders these cases of medical testing. It's clear that the Supreme Court has 'ruled that judges should be more flexible in determining if methods, rather than objects, are eligible for patents, citing emerging technologies such as medical testing.' So Bilski may result in dire news for medical methods and testing patents."